Pipeline Prioritization When Capital Is Scarce
The most consequential portfolio decision a clinical-stage board makes is rarely framed as a decision at all.
It happens quietly, by default, over a sequence of board meetings in which no one ever says the words. A company has three programs and enough runway to properly fund one and a half. Rather than confront that arithmetic, the board approves a budget that spreads the available capital across all three. Each program advances more slowly than it should. None reaches a value-creating milestone before the next financing. The company raises its next round from a position of weakness, having generated no decisive data on anything, and the cycle repeats. No single meeting produced this outcome. It was produced by the absence of a decision — by the board's unwillingness to say, explicitly, that some programs would be funded and others would not.
This is the prioritization problem, and it is one of the defining governance failures in clinical-stage biopharma. The failure is almost never a failure of analysis. The board can usually see, if it looks, which program has the strongest data and the clearest path. The failure is a failure of will: the unwillingness to concentrate resources in the face of the emotional, political, and scientific pressures that push toward spreading them thin.
Why Spreading Capital Feels Safer and Is Not
The instinct to fund everything a little is psychologically understandable. Each program represents years of work, the conviction of the scientists who championed it, and a real shot — however small — at being the asset that makes the company. Killing a program, or even slowing it, feels like conceding that the bet was wrong. It means disappointing the people who built it. It forecloses an option. And in a business defined by binary, low-probability outcomes, foreclosing any option feels dangerous.
But the arithmetic of clinical development does not reward optionality for its own sake. A program advanced at half speed is not half as valuable as a program advanced at full speed. In many cases it is worth nothing at all, because it never reaches the milestone that would attract the next round of capital or a partner. Value in biopharma is created at discrete inflection points — a positive readout, a successful end-of-Phase-II meeting, a partnership — and reaching those points requires concentrated resources, not distributed ones. A company that funds three programs to the point where none of them reaches an inflection has not diversified its risk. It has guaranteed its failure across a wider surface.
The board's job is to internalize that the scarce resource is not just capital. It is also time, management attention, and the credibility the company has with its investors. Spreading thin depletes all of these simultaneously. The discipline of concentration — funding the lead program to a decisive milestone before committing serious capital to the rest — is not the riskier path. It is the one most likely to produce a result that justifies the next financing.
What the Board Is Actually Governing
It is worth being precise about the board's role here, because prioritization is a domain where boards routinely either overreach or abdicate.
The board is not choosing which molecule has the better mechanism. That is a scientific judgment that belongs to management and the scientific advisory board, and a director who tries to adjudicate the underlying biology is misusing the role. What the board governs is the allocation of capital against the company's strategic objectives and runway — the portfolio-level question of how the company's finite resources are deployed to maximize the probability of creating value before the money runs out.
That distinction matters in practice. When management presents a pipeline, the board's questions should not be "is this the right target?" but rather: How much would it cost to bring each program to its next value-creating milestone? How long would that take? What is the financing environment likely to be at that point? If we fund all of these at the proposed levels, when do we run out of cash, and what data will we have generated by then? These are governance questions, not scientific ones, and they are precisely the questions that get lost when the board defers entirely to management's enthusiasm for the pipeline.
The board is also governing the honesty of the prioritization process itself. Management has structural incentives that work against concentration. Program champions advocate for their programs. The CSO may be reluctant to kill a project that reflects years of the team's work. The CEO may want to preserve optionality to keep multiple narratives alive for investors. None of these incentives is malicious, but together they create a systematic bias toward spreading capital. One of the board's most useful functions is to be the body in the room that is structurally indifferent to which program wins — and therefore able to ask the concentrating question that management is conflicted about asking.
A Framework for the Conversation
The most effective prioritization discussions I have seen share a common structure. They begin not with the programs but with the runway.
The board and management establish, before discussing any individual asset, how much capital is actually available and how long it lasts under different spending scenarios. This grounds the entire conversation in the real constraint. It is much harder to approve funding all three programs once everyone in the room has acknowledged that doing so means running out of cash four months before the lead program reads out.
With the constraint established, each program is then assessed on a small number of dimensions that the board can actually evaluate: the cost and time to its next value-creating milestone, the probability that the milestone is reached, the magnitude of value created if it is, and the strategic fit with what the company is trying to become. The point of this exercise is not false precision. The probabilities are estimates and everyone knows it. The point is to force an explicit comparison rather than an implicit one — to put the programs side by side and make the trade-offs visible.
What typically emerges is a ranking, and with it the uncomfortable recognition that the available capital supports the top program or two, not all of them. This is where the governance work actually happens. The board must decide, explicitly, what gets funded to a milestone, what gets maintained at a minimal level pending more data or capital, and what gets stopped. And it must require that the decision be communicated honestly inside the company, rather than allowed to happen by the slow starvation that lets everyone pretend no decision was made.
The Discipline of Killing Programs
The hardest part of prioritization is not choosing the winner. It is stopping the losers, and stopping them cleanly.
A program that is starved rather than killed continues to consume resources — not only the modest capital still allocated to it, but the management attention, the laboratory space, the regulatory bandwidth, and the psychological energy of a team that knows, on some level, that the program is not really going anywhere. The cost of indecision is paid continuously and invisibly. A clean kill, by contrast, frees those resources immediately and redirects them to the programs that can actually create value.
Boards that are good at this treat program termination as a normal, expected feature of portfolio management rather than as an admission of failure. The expected number of programs that survive to approval in any clinical-stage portfolio is small; killing programs is what the process is supposed to produce. A board that has never killed a program is not a board with an unusually good pipeline. It is a board that has not been doing its job.
There is also a credibility dimension. Investors who watch a company make a hard, well-reasoned decision to concentrate its capital — to kill a program in order to fund the lead asset properly — generally read that as a sign of disciplined management, not weakness. The narrative of "we made a hard call to focus on our strongest opportunity" is a far better one to carry into a financing than "we are advancing a broad pipeline," which sophisticated investors correctly hear as "we have not decided what we are."
When the Pressure Runs the Other Way
It is worth acknowledging the opposite failure mode, because boards that have absorbed the discipline of concentration can overcorrect into a different mistake.
Concentration is the right default when capital is scarce and the programs are genuinely comparable in stage and quality. But there are situations where preserving a second program is the correct call — where the lead asset carries a specific, identifiable risk of binary failure, and the second program represents a genuine and inexpensive hedge against that risk rather than a diffusion of focus. The distinction is whether the second program is being funded as a real strategic hedge with its own logic, or simply because no one wanted to kill it. A board should be willing to fund a deliberate hedge. It should not let the language of "hedging" become a respectable cover for the failure to concentrate.
The test is specificity. A board funding a true hedge can articulate exactly what risk it is hedging, why the hedge is worth its cost, and what evidence would cause it to either commit further or stop. A board that cannot answer those questions is not hedging. It is spreading thin and telling itself a more flattering story about it.
The Decision That Defines the Company
Pipeline prioritization is, in the end, the decision that determines what kind of company exists in two years. A board that concentrates capital on its strongest asset and drives it to a decisive milestone gives the company a real chance to create value and raise its next round from strength. A board that funds everything a little, year after year, produces a company that is perpetually mid-stage on multiple fronts, perpetually under-capitalized, and perpetually one disappointing readout away from a down round or a shutdown.
The decision is hard precisely because it requires the board to do the thing that feels least natural: to choose, explicitly and on the record, that some of the company's work will not be funded. But that choice is the essence of governance under scarcity. The board that makes it well is not the one with the most programs or the smartest individual directors. It is the one that has the discipline to concentrate its finite resources where they are most likely to create value, and the will to say so out loud.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.